Ionis Pharmaceuticals (IONS) Projected to Post Quarterly Earnings on Wednesday

Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) will likely be releasing its Q1 2025 earnings data before the market opens on Wednesday, April 30th. Analysts expect the company to announce earnings of ($1.07) per share and revenue of $144.31 million for the quarter. Ionis Pharmaceuticals has set its FY 2025 guidance at EPS.

Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last announced its quarterly earnings data on Wednesday, February 19th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.12) by $0.46. Ionis Pharmaceuticals had a negative net margin of 64.25% and a negative return on equity of 100.05%. The company had revenue of $227.00 million during the quarter, compared to analysts' expectations of $140.97 million. During the same period in the previous year, the company earned $0.12 EPS. The business's quarterly revenue was down 30.2% compared to the same quarter last year. On average, analysts expect Ionis Pharmaceuticals to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Ionis Pharmaceuticals Trading Down 0.0 %

Ionis Pharmaceuticals stock traded down $0.01 during midday trading on Monday, reaching $29.69. The stock had a trading volume of 159,463 shares, compared to its average volume of 1,526,176. The stock has a market capitalization of $4.72 billion, a PE ratio of -9.77 and a beta of 0.29. The company has a debt-to-equity ratio of 2.12, a quick ratio of 8.82 and a current ratio of 8.47. The stock's 50-day simple moving average is $30.68 and its 200 day simple moving average is $33.87. Ionis Pharmaceuticals has a twelve month low of $23.95 and a twelve month high of $52.34.

Insider Buying and Selling at Ionis Pharmaceuticals

In related news, EVP Patrick R. O'neil sold 1,207 shares of the company's stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $32.35, for a total transaction of $39,046.45. Following the sale, the executive vice president now directly owns 56,245 shares of the company's stock, valued at approximately $1,819,525.75. This represents a 2.10 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Eric Swayze sold 1,367 shares of Ionis Pharmaceuticals stock in a transaction on Friday, January 31st. The stock was sold at an average price of $32.31, for a total transaction of $44,167.77. Following the completion of the transaction, the executive vice president now directly owns 48,017 shares of the company's stock, valued at approximately $1,551,429.27. This represents a 2.77 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 63,167 shares of company stock worth $2,010,458 over the last quarter. 2.71% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. HC Wainwright initiated coverage on shares of Ionis Pharmaceuticals in a report on Monday, April 7th. They issued a "buy" rating and a $45.00 price target on the stock. Guggenheim reaffirmed a "buy" rating on shares of Ionis Pharmaceuticals in a research report on Thursday, April 3rd. BMO Capital Markets cut their price objective on Ionis Pharmaceuticals from $60.00 to $45.00 and set a "market perform" rating on the stock in a research report on Thursday, February 20th. StockNews.com raised Ionis Pharmaceuticals to a "sell" rating in a research report on Tuesday, March 18th. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $70.00 target price on shares of Ionis Pharmaceuticals in a report on Thursday, February 20th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Ionis Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $56.72.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.